Ratings IRADIMED CORPORATION

Equities

IRMD

US46266A1097

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
41.86 ^USD	+0.94%		+2.10%	-11.82%

Apr. 03	IRadimed Files $75 Million Common Stock Shelf Registration	MT
Feb. 08	Transcript : IRadimed Corporation, Q4 2023 Earnings Call, Feb 08, 2024

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

The group's activity appears highly profitable thanks to its outperforming net margins.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 30.33 times its estimated earnings per share for the ongoing year.
For the last few months, analysts have been revising downwards their earnings forecast.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
IRADIMED CORPORATION	-11.82%	530M	D+
SHOCKWAVE MEDICAL, INC.	+73.17%	12.38B	B-
PENUMBRA, INC.	-18.74%	7.92B	C+
MASIMO CORPORATION	+16.15%	7.2B	C-
GETINGE AB	+4.81%	5.84B	B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+5.99%	5.07B	D+
APT MEDICAL INC.	+27.07%	4.53B	-
ASAHI INTECC CO., LTD.	-21.67%	3.88B	B-
INARI MEDICAL, INC.	-40.82%	2.23B	C
SKAN GROUP AG	+1.49%	2.02B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes